Home › Trial NCT01221506
Pazopanib/DCE-MRIs in Renal Cell Carcinoma (RCC)
- Trial IDNCT01221506
- StatusCompleted
- PhaseEarly Phase 1
- Study typeInterventional
- SponsorAbramson Cancer Center at Penn Medicine
- Enrollment20
- Start date2010-10
- ConditionsCarcinoma, Renal Cell
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.